论文部分内容阅读
乙型肝炎病毒(HBV)表面有一种具有多聚人白蛋白(pHSA)受体活性的蛋白,这种受体蛋白在完整病毒(Dane颗粒)和22nm的乙型肝炎表面颗粒的亚群上均可发现.这种受体的抗体(抗-pHSA-受体)可能与阻断病毒进入肝细胞而降低HBV感染有关.Coursaget等指出,含有pHSA受体的p~(34)和p~(36)多肽疫苗比缺乏这些受体的疫苗有更高的免疫原性.作者对Merck药厂生产的疫苗检测了pHSA受体活性,在用戊二醛聚合的人白蛋白致敏的试管中作ELISA,结合物用抗-HBs过氧化物酶显示.
On the surface of Hepatitis B virus (HBV), there is a protein that has the activity of polySA (human albumin) (pHSA), which is expressed on the subgroup of complete virus (Dane particles) and 22 nm Hepatitis B surface particles (Anti-pHSA-receptor) may be related to blocking the virus into the liver cells and reduce HBV infection.Coursaget, etc., pointed out that pHSA receptor containing p ~ (34) and p ~ (36 ) Peptide vaccines have a higher immunogenicity than vaccines lacking these receptors.The authors tested the pHSA receptor activity of vaccines produced by Merck and performed ELISA in glutaraldehyde-primed human albumin-primed tubes , The conjugate is shown by anti-HBs peroxidase.